You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ):磷酸奧司他韋收到化學原料藥CEP證書
格隆匯 07-28 19:28

格隆匯7月28日丨金城醫藥(300233.SZ)公佈,公司之全資子公司北京金城泰爾製藥有限公司(簡稱“金城泰爾”)於近日收到歐洲藥品質量管理局(EDQM)核准簽發的磷酸奧司他韋化學原料藥歐洲藥典適用性證書(簡稱“CEP證書”)。磷酸奧司他韋是一種選擇性的流感病毒神經氨酸酶抑制劑,可以抑制病毒在體內進一步擴散,由羅氏公司研製開發。目前國內磷酸奧司他韋的相關劑型為膠囊、顆粒劑和幹混懸劑,臨牀上主要適用於成人、1歲及1歲以上兒童的甲型和乙型流感治療,成人、13歲及13歲以上青少年的甲型和乙型流感的預防。根據IMS數據查詢,2023年全球製劑銷售額8.74億美元,原料藥消耗69.99噸。2024年全球製劑銷售額10.17億美元,原料藥消耗92.31噸。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account